{
  "case_id": "Case_5",
  "model_id": "openai/gpt-oss-120b",
  "content": "{\n    \"primary_diagnosis\": {\n        \"name\": \"Idiopathic Parkinson disease\",\n        \"confidence\": 0.72,\n        \"icd_code\": \"G20\",\n        \"reasoning\": \"Classic triad of resting tremor, bradykinesia, and rigidity with a subacute onset over months; basal ganglia MRI is often normal or shows subtle nonspecific changes. Lack of exposure timeline strongly supporting a primary neurodegenerative process.\"\n    },\n    \"differential_diagnoses\": [\n        {\n            \"name\": \"Manganese-induced parkinsonism (secondary parkinsonism)\",\n            \"confidence\": 0.45,\n            \"icd_code\": \"G21.2\",\n            \"reasoning\": \"Work in water purification in Bangladesh may involve exposure to manganese or other metals; basal ganglia signal changes can be seen. Symptoms overlap but often have less resting tremor and more gait disturbance.\"\n        },\n        {\n            \"name\": \"Wilson disease (copper accumulation)\",\n            \"confidence\": 0.30,\n            \"icd_code\": \"E83.0\",\n            \"reasoning\": \"Can present with movement disorder and basal ganglia MRI abnormalities in adults; however, hepatic symptoms and younger typical onset make it less likely.\"\n        },\n        {\n            \"name\": \"Drug\u2011induced parkinsonism\",\n            \"confidence\": 0.25,\n            \"icd_code\": \"G21.1\",\n            \"reasoning\": \"Consider if patient used dopamine\u2011blocking agents (e.g., antipsychotics) during the overseas assignment; history not provided but must be ruled out.\"\n        }\n    ],\n    \"key_findings\": [\n        \"Progressive resting tremor, bradykinesia, rigidity over 3 months\",\n        \"Subtle basal ganglia signal abnormalities on MRI\"\n    ],\n    \"diagnostic_tests\": [\n        {\n            \"test\": \"Serum manganese level\",\n            \"purpose\": \"Rule in/out manganese toxicity as cause of secondary parkinsonism\",\n            \"priority\": \"urgent\"\n        },\n        {\n            \"test\": \"Serum ceruloplasmin, copper, 24\u2011hour urinary copper\",\n            \"purpose\": \"Exclude Wilson disease\",\n            \"priority\": \"urgent\"\n        },\n        {\n            \"test\": \"DaTscan (123I\u2011FP\u2011CIT SPECT)\",\n            \"purpose\": \"Differentiate neurodegenerative Parkinson disease from drug\u2011induced or functional causes\",\n            \"priority\": \"routine\"\n        },\n        {\n            \"test\": \"Comprehensive medication review and toxicology screen\",\n            \"purpose\": \"Identify possible dopamine\u2011blocking agents or other neurotoxic exposures\",\n            \"priority\": \"routine\"\n        }\n    ],\n    \"management_plan\": {\n        \"immediate_actions\": [\n            \"Refer to movement\u2011disorder neurologist for confirmation and initiation of therapy\",\n            \"Order urgent serum manganese and copper studies\"\n        ],\n        \"medications\": [\n            {\n                \"drug\": \"Levodopa/Carbidopa\",\n                \"dose\": \"25/100 mg PO three times daily\",\n                \"route\": \"PO\",\n                \"duration\": \"Start now, titrate based on response\",\n                \"rationale\": \"First\u2011line symptomatic treatment for Parkinson disease; improves bradykinesia and rigidity\"\n            },\n            {\n                \"drug\": \"Pramipexole\",\n                \"dose\": \"0.125 mg PO once daily, titrate up to 1.5 mg/day as needed\",\n                \"route\": \"PO\",\n                \"duration\": \"Adjunct if levodopa insufficient or for tremor control\",\n                \"rationale\": \"Dopamine agonist useful in early disease and may reduce levodopa dose\"\n            }\n        ],\n        \"monitoring\": [\n            \"Motor symptom severity (UPDRS) \u2013 every 3 months\",\n            \"Medication side effects (nausea, orthostatic hypotension, dyskinesia) \u2013 each visit\",\n            \"Serum manganese and copper levels if initially abnormal \u2013 repeat in 3 months\"\n        ],\n        \"consultations\": [\n            {\n                \"specialty\": \"Neurology \u2013 movement disorders\",\n                \"urgency\": \"immediate\",\n                \"reason\": \"Confirm diagnosis, start disease\u2011specific therapy, arrange DaTscan\"\n            },\n            {\n                \"specialty\": \"Occupational medicine / Toxicology\",\n                \"urgency\": \"urgent\",\n                \"reason\": \"Evaluate possible environmental metal exposure and advise on remediation\"\n            }\n        ]\n    },\n    \"red_flags\": [\n        \"Rapid progression of symptoms within weeks\",\n        \"Development of gait instability, falls, or early cognitive decline\",\n        \"New onset visual hallucinations or psychosis\"\n    ],\n    \"patient_education\": [\n        \"Parkinson disease is a progressive neurodegenerative disorder; medications can markedly improve quality of life.\",\n        \"Environmental exposures can mimic or worsen symptoms, but treatment focuses on the underlying neurobiology; unnecessary avoidance of all exposures without evidence may cause anxiety.\"\n    ],\n    \"follow_up\": {\n        \"timing\": \"Neurology appointment within 2 weeks; primary care follow\u2011up in 4\u20136 weeks\",\n        \"conditions\": \"Worsening tremor, new gait instability, severe medication side effects, or abnormal toxin labs require immediate return\"\n    },\n    \"confidence_in_assessment\": 0.78,\n    \"uncertainties\": [\n        \"Exact level and duration of manganese or other metal exposure during overseas assignment\",\n        \"Potential undisclosed use of dopamine\u2011blocking medications while abroad\"\n    ]\n}",
  "latency": 6.953974962234497,
  "timestamp": "2025-08-10T01:15:58.063711",
  "cached_at": "2025-08-10T01:15:58.063715"
}